Ob/gyns must be aware of the different treatment recommendations for various scenarios pre- and post-delivery.
Women with prior VTE-especially if the episode was associated with pregnancy or use of estrogen-containing oral contraceptives-are at increased risk for recurrent VTE during pregnancy or postpartum. VTE risk also is increased in women with high-risk thrombophilias. Women with prior VTE and low-risk thrombophilias also are at increased risk. These data led to clear recommendations from the American College of Obstetricians and Gynecologists (ACOG) for antepartum and postpartum prophylaxis for women with prior VTE and/or thrombophilias.1,2
Related: A simple step to reduce maternal death: Improve VTE prevention
Thromboprophylaxis is almost always initiated after vaginal delivery or cesarean, typically at least 6 hours later. This allows for safe administration of neuraxial analgesia or anesthesia and removal of a catheter. However, VTE may already have formed by that time, in which case, prophylaxis may be useless or less effective compared to when it is used prior to and during surgery. Another knowledge gap is the optimal duration of thromboprophylaxis. Heparin or low-molecular-weight heparin (LMWH) may be continued until the patient is ambulatory, until she is discharged from the hospital, through 10 days after delivery or 6 weeks after delivery.3 The relative merits of each time interval are uncertain. The same is true for various doses and drugs used for thromboprophylaxis. Although knowledge gaps exist, ACOG has a practice bulletin summarizing available regimens.2
The authors report no potential conflicts of interest.
Chemoattractants in fetal membranes enhance leukocyte migration near term pregnancy
November 22nd 2024A recent study highlights the release of chemoattractants from human fetal membranes at term, driving leukocyte activation and migration, with implications for labor and postpartum recovery.
Read More
Reproductive genetic carrier screening: A tool for reproductive decision-making
November 22nd 2024A new study highlights the efficacy of couple-based reproductive genetic carrier screening in improving reproductive decisions and outcomes, emphasizing its growing availability and acceptance among diverse populations.
Read More
Early preterm birth risk linked to low PlGF levels during pregnancy screening
November 20th 2024New research highlights that low levels of placental growth factor during mid-pregnancy screening can effectively predict early preterm birth, offering a potential tool to enhance maternal and infant health outcomes.
Read More